Safety profile of celiprolol.
Author(s): Lamon KD
Affiliation(s): Rorer Central Reseach, Horsham, PA 19044.
Publication date & source: 1988-11, Am Heart J., 116(5 Pt 2):1438-40.
Publication type: Clinical Trial; Comparative Study ; Review
Celiprolol hydrochloride is a highly cardioselective beta1-adrenergic antagonist with a unique pharmacologic profile. The adverse experience safety data derived from 18 double-blind trials (n = 2884) were evaluated. The results demonstrated a wide margin of safety for celiprolol over the recommended dosage range of 200 to 600 mg once daily. Celiprolol exhibited an adverse experience profile similar to that of placebo and resulted in a lower incidence of bradycardia and age-associated increases in adverse event rates compared with atenolol and propranolol.